GR20010300010T1 - Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas - Google Patents

Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas

Info

Publication number: GR20010300010T1
Authority: GR; Greece
Prior art keywords: inhibition; aryl; raf kinase; substituted heterocyclic; heteroaryl substituted
Prior art date: 1997-12-22

Application number

GR20010300010T

Other languages

English (en)

Inventor

Jacques Dumas

Uday Khire

Timothy Bruno Lowinger

Bernd Riedl

William J Scott

Roger A Smith

Jill E Wood

Holia Hatoum-Mokdad

Jeffrey Johnson

Aniko Redman

Robert Sibley

Original Assignee

Bayer Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-12-22

Filing date

2001-03-30

Publication date

2001-03-30

2001-03-30 Application filed by Bayer Ag filed Critical Bayer Ag

2001-03-30 Publication of GR20010300010T1 publication Critical patent/GR20010300010T1/el

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)

GR20010300010T 1997-12-22 2001-03-30 Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas GR20010300010T1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US99618197A	1997-12-22	1997-12-22
PCT/US1998/026082 WO1999032455A1 (en)	1997-12-22	1998-12-22	Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas

Publications (1)

Publication Number	Publication Date
GR20010300010T1 true GR20010300010T1 (en)	2001-03-30

Family

ID=25542594

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GR20010300010T GR20010300010T1 (en)	1997-12-22	2001-03-30	Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas

Country Status (28)

Country	Link
EP (1)	EP1056725B1 (el)
JP (1)	JP4395823B2 (el)
KR (1)	KR100622138B1 (el)
CN (1)	CN1117081C (el)
AT (1)	ATE328873T1 (el)
AU (1)	AU765412B2 (el)
BG (1)	BG65207B1 (el)
BR (1)	BR9814361A (el)
CA (1)	CA2315713C (el)
CU (1)	CU23127A3 (el)
CY (1)	CY1105395T1 (el)
CZ (1)	CZ299836B6 (el)
DE (2)	DE69834842T2 (el)
DK (1)	DK1056725T3 (el)
ES (1)	ES2155045T3 (el)
GR (1)	GR20010300010T1 (el)
HU (1)	HUP0004426A3 (el)
ID (1)	ID26328A (el)
IL (2)	IL136773A0 (el)
NO (1)	NO319209B1 (el)
NZ (1)	NZ505845A (el)
PL (1)	PL341356A1 (el)
PT (1)	PT1056725E (el)
RU (1)	RU2265597C2 (el)
SK (1)	SK285371B6 (el)
TR (3)	TR200100918T2 (el)
UA (1)	UA67763C2 (el)
WO (1)	WO1999032455A1 (el)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1473292A1 (en) *	1997-11-03	2004-11-03	Boehringer Ingelheim Pharmaceuticals, Inc.	Aromatic heterocyclic compounds as anti-inflammatory agents
EP1041982B1 (en) *	1997-12-22	2011-10-19	Bayer HealthCare LLC	INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
US7329670B1 (en)	1997-12-22	2008-02-12	Bayer Pharmaceuticals Corporation	Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US7517880B2 (en)	1997-12-22	2009-04-14	Bayer Pharmaceuticals Corporation	Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
AU2006201959B2 (en) *	1997-12-22	2008-09-04	Bayer Healthcare Llc	Inhibition of Raf Kinase using Substituted Heterocyclic Ureas
DK1043995T3 (da) *	1997-12-22	2007-03-05	Bayer Pharmaceuticals Corp	Inhibering af p38 kinaseaktivitet ved anvendelse af aryl- og heteroaryl-substituerede, heterocykliske urinstoffer
PL205321B1 (pl) *	1997-12-22	2010-04-30	Bayer Corp	Zastosowanie podstawionych heterocyklicznych moczników do wytwarzania leku do hamowania kinazy raf, podstawione heterocykliczne moczniki oraz kompozycja farmaceutyczna je zawierająca
JP2002534468A (ja)	1999-01-13	2002-10-15	バイエルコーポレイション	ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
US8124630B2 (en)	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928239B2 (en) *	1999-01-13	2011-04-19	Bayer Healthcare Llc	Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
EP1140840B1 (en)	1999-01-13	2006-03-22	Bayer Pharmaceuticals Corp.	-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
RU2319693C9 (ru)	1999-01-13	2008-08-20	Байер Копэрейшн	Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
UA73492C2 (en)	1999-01-19	2005-08-15		Aromatic heterocyclic compounds as antiinflammatory agents
WO2000050425A1 (en)	1999-02-22	2000-08-31	Boehringer Ingelheim Pharmaceuticals, Inc.	Polycyclo heterocyclic derivatives as antiinflammatory agents
WO2000051998A1 (en)	1999-03-02	2000-09-08	Boehringer Ingelheim Pharmaceuticals, Inc.	Compounds useful as reversible inhibitors of cathepsin s
MXPA01009077A (es)	1999-03-12	2002-03-27	Boehringer Ingelheim Pharma	Composiciones heterociclicos aromaticos como agentes anti-inflamatorios.
ATE278674T1 (de)	1999-03-12	2004-10-15	Boehringer Ingelheim Pharma	Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel
DE60024830T2 (de)	1999-07-09	2006-06-14	Boehringer Ingelheim Pharma	Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
YU9602A (sh)	1999-08-12	2004-11-25	Pharmacia Italia S.P.A.	Derivati 3(5)-amino-pirazola, postupak za njihovu izradu i njihova upotreba kao antitumornih agenasa
US6420364B1 (en)	1999-09-13	2002-07-16	Boehringer Ingelheim Pharmaceuticals, Inc.	Compound useful as reversible inhibitors of cysteine proteases
US7026336B1 (en) *	1999-11-22	2006-04-11	Smithkline Beecham P.L.C.	Compounds
US6525046B1 (en)	2000-01-18	2003-02-25	Boehringer Ingelheim Pharmaceuticals, Inc.	Aromatic heterocyclic compounds as antiinflammatory agents
US6608052B2 (en)	2000-02-16	2003-08-19	Boehringer Ingelheim Pharmaceuticals, Inc.	Compounds useful as anti-inflammatory agents
PT1320531E (pt) *	2000-08-10	2010-10-27	Pfizer Italia Srl	Biciclo-pirazoles activos como inibidores da cinase, processo para a sua preparação e composições farmacêuticas compreendendo estes
US6645990B2 (en)	2000-08-15	2003-11-11	Amgen Inc.	Thiazolyl urea compounds and methods of uses
AU2002232439A1 (en)	2000-11-29	2002-06-11	Glaxo Group Limited	Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
US7235576B1 (en)	2001-01-12	2007-06-26	Bayer Pharmaceuticals Corporation	Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en)	2001-04-20	2008-05-13	Bayer Pharmaceuticals Corporation	Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
JP2004530690A (ja)	2001-05-16	2004-10-07	ベーリンガーインゲルハイムファーマシューティカルズインコーポレイテッド	抗炎症性薬剤として有用なジアリールウレア誘導体
GB0112348D0 (en)	2001-05-19	2001-07-11	Smithkline Beecham Plc	Compounds
EP1395561A1 (en)	2001-05-25	2004-03-10	Boehringer Ingelheim Pharmaceuticals Inc.	Carbamate and oxamide compounds as inhibitors of cytokine production
EP1709965A3 (en) *	2001-07-11	2006-12-27	Boehringer Ingelheim Pharmaceuticals, Inc.	Methods of treating cytokine mediate diseases
EP1423383B1 (en)	2001-09-05	2008-08-06	Smithkline Beecham Plc	Pyridine substituted furan derivatives as raf kinase inhibitors
DE60216139T3 (de) *	2001-12-03	2018-11-15	Bayer Healthcare Llc	Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
MXPA04007830A (es)	2002-02-11	2005-07-01	Bayer Pharmaceuticals Corp	Arilureas como inhibidores de cinasa.
US10653684B2 (en)	2002-02-11	2020-05-19	Bayer Healthcare Llc	Aryl ureas with angiogenisis inhibiting activity
US20040023961A1 (en) *	2002-02-11	2004-02-05	Bayer Corporation	Aryl ureas with raf kinase and angiogenisis inhibiting activity
SI1478358T1 (sl)	2002-02-11	2013-09-30	Bayer Healthcare Llc	Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
JP4629978B2 (ja)	2002-02-25	2011-02-09	ベーリンガーインゲルハイムファーマシューティカルズインコーポレイテッド	サイトカイン媒介疾患の治療に有用な１，４−二置換ベンゾ縮合シクロアルキル尿素化合物
AU2003244649A1 (en) *	2002-07-25	2004-02-23	Pharmacia Italia Spa	Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US7202257B2 (en)	2003-12-24	2007-04-10	Deciphera Pharmaceuticals, Llc	Anti-inflammatory medicaments
US7144911B2 (en)	2002-12-31	2006-12-05	Deciphera Pharmaceuticals Llc	Anti-inflammatory medicaments
UY28213A1 (es)	2003-02-28	2004-09-30	Bayer Pharmaceuticals Corp	Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
EP1608639A2 (en)	2003-02-28	2005-12-28	Bayer Pharmaceuticals Corporation	Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
EP1633758B1 (en)	2003-05-15	2011-11-23	Arqule, Inc.	Imidazothiazoles and imidazoxazole derivatives as inhibitors of p38
ATE366108T1 (de)	2003-05-20	2007-07-15	Bayer Pharmaceuticals Corp	Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
MY142799A (en)	2003-07-23	2010-12-31	Bayer Healthcare Llc	Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
WO2005048953A2 (en)	2003-11-13	2005-06-02	Ambit Biosciences Corporation	Amide derivatives as kinase modulators
TW200530236A (en)	2004-02-23	2005-09-16	Chugai Pharmaceutical Co Ltd	Heteroaryl phenylurea
US20060211752A1 (en)	2004-03-16	2006-09-21	Kohn Leonard D	Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
DE602005025988D1 (de) *	2004-03-19	2011-03-03	Dipharma Francis Srl	Zwischenprodukte für die herstellung von pramipexol
ATE517885T1 (de)	2004-04-30	2011-08-15	Bayer Healthcare Llc	Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs
US7829560B2 (en)	2004-07-08	2010-11-09	Arqule, Inc.	1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
MY191349A (en) *	2004-08-27	2022-06-17	Bayer Pharmaceuticals Corp	New pharmaceutical compositions for the treatment of hyper-proliferative disorders
WO2006044869A1 (en)	2004-10-19	2006-04-27	Arqule, Inc.	Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
GB0423554D0 (en) *	2004-10-22	2004-11-24	Cancer Rec Tech Ltd	Therapeutic compounds
EP1835934A4 (en) *	2004-12-23	2010-07-28	Deciphera Pharmaceuticals Llc	ENZYME MODULATORS AND TREATMENTS
GB0500435D0 (en) *	2005-01-10	2005-02-16	Novartis Ag	Organic compounds
ES2351612T3 (es)	2005-03-07	2011-02-08	Bayer Schering Pharma Aktiengesellschaft	Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer.
US8299252B2 (en)	2005-08-05	2012-10-30	Chugai Seiyaku Kabushiki Kaisha	Pyrazolopyridine and pyrrolopyridine multikinase inhibitors
DE102005037499A1 (de) *	2005-08-09	2007-02-15	Merck Patent Gmbh	Pyrazolderivate
EP1960394A2 (en) *	2005-11-15	2008-08-27	Bayer HealthCare AG	Pyrazolyl urea derivatives useful in the treatment of cancer
WO2007075650A2 (en) *	2005-12-21	2007-07-05	Bayer Healthcare Ag	Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders
EP2094268A2 (en)	2006-05-26	2009-09-02	Bayer HealthCare, LLC	Drug combinations with substituted diaryl ureas for the treatment of cancer
US7897762B2 (en)	2006-09-14	2011-03-01	Deciphera Pharmaceuticals, Llc	Kinase inhibitors useful for the treatment of proliferative diseases
CA2672951A1 (en)	2006-12-20	2008-07-03	Bayer Healthcare Llc	Hydroxy methyl phenyl pyrazolyl urea compound useful in the treatment of cancer
US7737149B2 (en) *	2006-12-21	2010-06-15	Astrazeneca Ab	N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
WO2008123963A1 (en)	2007-04-02	2008-10-16	Renovis, Inc.	Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof
AU2008251723A1 (en)	2007-04-20	2008-11-20	Deciphera Pharmaceuticals, Llc	Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
TW200940539A (en)	2008-02-29	2009-10-01	Array Biopharma Inc	RAF inhibitor compounds and methods of use thereof
MX2010009410A (es)	2008-02-29	2010-11-30	Array Biopharma Inc	Compuestos del inhibidor de raf y métodos de uso de los mismos.
GB0818033D0 (en)	2008-10-02	2008-11-05	Respivert Ltd	Novel compound
EP2350049B1 (en)	2008-10-02	2014-02-26	Respivert Limited	P38 map kinase inhibitors
BRPI0922962A2 (pt)	2008-12-11	2019-09-24	Respivert Ltd	inibidores de p38 map quinase
GB0905955D0 (en)	2009-04-06	2009-05-20	Respivert Ltd	Novel compounds
JP5787976B2 (ja)	2010-04-08	2015-09-30	レスピバート・リミテツド	Ｐ３８ｍａｐキナーゼ阻害剤としてのピラゾリルウレア
CN103003262A (zh)	2010-07-16	2013-03-27	协和发酵麒麟株式会社	含氮芳香族杂环衍生物
JP2013531067A (ja)	2010-07-19	2013-08-01	バイエルヘルスケアリミティドライアビリティカンパニー	疾病及び状態の処置及び予防のためのフルオロ置換オメガ−カルボキシアリールジフェニル尿素を用いた組み合わせ薬
EP2763984B1 (en)	2011-10-03	2016-04-20	Respivert Limited	1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 map kinase inhibitors
EP2578582A1 (en)	2011-10-03	2013-04-10	Respivert Limited	1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
US8461179B1 (en)	2012-06-07	2013-06-11	Deciphera Pharmaceuticals, Llc	Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
KR20140011780A (ko)	2012-07-19	2014-01-29	한미약품 주식회사	단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체
GB201214750D0 (en)	2012-08-17	2012-10-03	Respivert Ltd	Compounds
GB201215357D0 (en)	2012-08-29	2012-10-10	Respivert Ltd	Compounds
US20160016934A1 (en)	2013-03-14	2016-01-21	Respivert Limited	Kinase inhibitors
US9750723B2 (en)	2013-10-31	2017-09-05	Ohio University	Prevention and treatment of non-alcoholic fatty liver disease
JP6586098B2 (ja)	2014-02-14	2019-10-02	レスピバート・リミテツド	キナーゼ阻害剤としてのピラゾリル尿素
US10392381B2 (en)	2014-07-18	2019-08-27	Ohio University	Prevention and treatment of non-alcoholic fatty liver disease
CN111886006B (zh)	2018-01-31	2024-07-09	德西费拉制药有限责任公司	治疗肥大细胞增多症的组合疗法
CN118557737A (zh)	2018-01-31	2024-08-30	德西费拉制药有限责任公司	治疗胃肠道间质瘤的组合疗法
US10669262B2 (en)	2018-03-08	2020-06-02	Incyte Corporation	Aminopyrazine diol compounds as PI3K-γ inhibitors
CN108484587A (zh) *	2018-06-03	2018-09-04	刘思良	一种Raf激酶抑制剂及其在癌症治疗中的应用
US11046658B2 (en)	2018-07-02	2021-06-29	Incyte Corporation	Aminopyrazine derivatives as PI3K-γ inhibitors
EP3818044A1 (en) *	2018-07-03	2021-05-12	IFM Due, Inc.	Compounds and compositions for treating conditions associated with sting activity
CN114615982A (zh)	2019-08-12	2022-06-10	德西费拉制药有限责任公司	用于治疗胃肠道间质瘤的瑞普替尼
TWI878335B (zh)	2019-08-12	2025-04-01	美商迪賽孚爾製藥有限公司	治療胃腸道基質瘤方法
KR20250060322A (ko)	2019-12-30	2025-05-07	데시페라 파마슈티칼스, 엘엘씨	비정질 키나아제 억제제 제형 및 이의 사용 방법
CN115243681B (zh)	2019-12-30	2024-08-16	德西费拉制药有限责任公司	1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
US11779572B1 (en)	2022-09-02	2023-10-10	Deciphera Pharmaceuticals, Llc	Methods of treating gastrointestinal stromal tumors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4994455A (en) *	1987-10-26	1991-02-19	Pfizer Inc.	Anti-anxiety agents
US5162360A (en) *	1991-06-24	1992-11-10	Warner-Lambert Company	2-heteroatom containing urea and thiourea ACAT inhibitors
GB9302275D0 (en) *	1993-02-05	1993-03-24	Smithkline Beecham Plc	Novel compounds
US5773459A (en) *	1995-06-07	1998-06-30	Sugen, Inc.	Urea- and thiourea-type compounds
GB9623833D0 (en) *	1996-11-16	1997-01-08	Zeneca Ltd	Chemical compound
ATE399007T1 (de) *	1997-05-23	2008-07-15	Bayer Pharmaceuticals Corp	Raf kinase hemmer
AU1367599A (en) *	1997-11-03	1999-05-24	Boehringer Ingelheim Pharmaceuticals, Inc.	Aromatic heterocyclic compounds as anti-inflammatory agents
DK1043995T3 (da) *	1997-12-22	2007-03-05	Bayer Pharmaceuticals Corp	Inhibering af p38 kinaseaktivitet ved anvendelse af aryl- og heteroaryl-substituerede, heterocykliske urinstoffer

1998
- 1998-12-22 IL IL13677398A patent/IL136773A0/xx active IP Right Grant
- 1998-12-22 RU RU2000120162/04A patent/RU2265597C2/ru not_active IP Right Cessation
- 1998-12-22 NZ NZ505845A patent/NZ505845A/en not_active IP Right Cessation
- 1998-12-22 UA UA2000074353A patent/UA67763C2/uk unknown
- 1998-12-22 DE DE69834842T patent/DE69834842T2/de not_active Expired - Lifetime
- 1998-12-22 TR TR2001/00918T patent/TR200100918T2/xx unknown
- 1998-12-22 WO PCT/US1998/026082 patent/WO1999032455A1/en active IP Right Grant
- 1998-12-22 PL PL98341356A patent/PL341356A1/xx not_active Application Discontinuation
- 1998-12-22 DE DE1056725T patent/DE1056725T1/de active Pending
- 1998-12-22 SK SK962-2000A patent/SK285371B6/sk not_active IP Right Cessation
- 1998-12-22 AT AT98963810T patent/ATE328873T1/de active
- 1998-12-22 ES ES98963810T patent/ES2155045T3/es not_active Expired - Lifetime
- 1998-12-22 CZ CZ20002349A patent/CZ299836B6/cs not_active IP Right Cessation
- 1998-12-22 HU HU0004426A patent/HUP0004426A3/hu unknown
- 1998-12-22 AU AU19055/99A patent/AU765412B2/en not_active Ceased
- 1998-12-22 CN CN98812504A patent/CN1117081C/zh not_active Expired - Fee Related
- 1998-12-22 KR KR1020007007014A patent/KR100622138B1/ko not_active Expired - Fee Related
- 1998-12-22 PT PT98963810T patent/PT1056725E/pt unknown
- 1998-12-22 DK DK98963810T patent/DK1056725T3/da active
- 1998-12-22 TR TR2000/02617T patent/TR200002617T2/xx unknown
- 1998-12-22 TR TR2001/00917T patent/TR200100917T2/xx unknown
- 1998-12-22 ID IDW20001417A patent/ID26328A/id unknown
- 1998-12-22 CA CA2315713A patent/CA2315713C/en not_active Expired - Fee Related
- 1998-12-22 JP JP2000525392A patent/JP4395823B2/ja not_active Expired - Fee Related
- 1998-12-22 BR BR9814361-1A patent/BR9814361A/pt not_active IP Right Cessation
- 1998-12-22 EP EP98963810A patent/EP1056725B1/en not_active Expired - Lifetime
2000
- 2000-06-14 IL IL136773A patent/IL136773A/en not_active IP Right Cessation
- 2000-06-21 NO NO20003231A patent/NO319209B1/no not_active IP Right Cessation
- 2000-06-22 CU CU152A patent/CU23127A3/es not_active IP Right Cessation
- 2000-07-12 BG BG104598A patent/BG65207B1/bg unknown
2001
- 2001-03-30 GR GR20010300010T patent/GR20010300010T1/el unknown
2006
- 2006-09-06 CY CY20061101275T patent/CY1105395T1/el unknown

Also Published As

Publication number	Publication date
PT1056725E (pt)	2006-09-29
UA67763C2 (uk)	2004-07-15
SK285371B6 (sk)	2006-12-07
ES2155045T1 (es)	2001-05-01
TR200100917T2 (tr)	2001-07-23
KR100622138B1 (ko)	2006-09-13
CA2315713C (en)	2011-02-01
PL341356A1 (en)	2001-04-09
JP4395823B2 (ja)	2010-01-13
BG65207B1 (bg)	2007-07-31
CU23127A3 (es)	2006-04-18
DK1056725T3 (da)	2006-10-02
ES2155045T3 (es)	2007-02-01
RU2265597C2 (ru)	2005-12-10
DE69834842D1 (de)	2006-07-20
NO20003231L (no)	2000-08-22
TR200100918T2 (tr)	2001-06-21
TR200002617T2 (tr)	2000-11-21
CZ299836B6 (cs)	2008-12-10
HK1029989A1 (en)	2001-04-20
DE1056725T1 (de)	2001-06-07
KR20010033513A (ko)	2001-04-25
JP2001526269A (ja)	2001-12-18
NZ505845A (en)	2003-10-31
DE69834842T2 (de)	2007-05-10
EP1056725B1 (en)	2006-06-07
ID26328A (id)	2000-12-14
CN1283192A (zh)	2001-02-07
ATE328873T1 (de)	2006-06-15
EP1056725A4 (en)	2001-02-07
IL136773A0 (en)	2001-06-14
HUP0004426A2 (hu)	2001-05-28
BR9814361A (pt)	2001-11-27
CY1105395T1 (el)	2010-07-28
CZ20002349A3 (en)	2001-05-16
BG104598A (en)	2001-02-28
AU765412B2 (en)	2003-09-18
NO20003231D0 (no)	2000-06-21
CA2315713A1 (en)	1999-07-01
HUP0004426A3 (en)	2001-07-30
AU1905599A (en)	1999-07-12
IL136773A (en)	2006-10-31
EP1056725A1 (en)	2000-12-06
NO319209B1 (no)	2005-06-27
SK9622000A3 (en)	2001-01-18
WO1999032455A1 (en)	1999-07-01
CN1117081C (zh)	2003-08-06

Publication	Publication Date	Title
GR20010300010T1 (en)	2001-03-30	Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas
PL343083A1 (en)	2001-07-30	Inhibition of raf kinase using substituted heterocyclic ureas
GR20010300033T1 (en)	2001-06-29	Raf kinase inhibitors
SI1070056T1 (en)	2004-12-31	Phthalazinone pde iii/iv inhibitors
CA2291222A1 (en)	1999-02-25	Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
UA66865C2 (uk)	2004-06-15	Інденопіролокарбазоли, фармацевтична композиція, спосіб інгібування кіназної активності та спосіб лікування (варіанти)
ATE296809T1 (de)	2005-06-15	3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
ATE281439T1 (de)	2004-11-15	3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
AU2003204708A1 (en)	2003-07-17	Inhibition of Raf Kinase using Substituted Heterocyclic Ureas
SI1056725T1 (sl)	2006-10-31	Inhibicija RAF-kinaze z uporabo arilno in heteroarilno substituiranih heterociklicnih secnin
SI1047418T1 (sl)	2005-12-31	Inhibicija raf-kinaze z uporabo substituiranih heterociklicnih secnin